Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
about
Effect of Mukitake mushroom (Panellus serotinus) on the pathogenesis of lipid abnormalities in obese, diabetic ob/ob miceESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryMolecular processes that handle -- and mishandle -- dietary lipidsTriglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in HumansInteraction between Glucose and Lipid Metabolism: More than Diabetic DyslipidemiaPPP2R5C Couples Hepatic Glucose and Lipid HomeostasisSugar consumption, metabolic disease and obesity: The state of the controversyWhy Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?Low-normal thyroid function and novel cardiometabolic biomarkersHealth disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statementA computational model for the analysis of lipoprotein distributions in the mouse: translating FPLC profiles to lipoprotein metabolismReduced apolipoprotein glycosylation in patients with the metabolic syndromeNew function for an old enzyme: NEP deficient mice develop late-onset obesityMetabolic features of chronic fatigue syndromeThe genetic architecture of lipoprotein subclasses in Gullah-speaking African American families enriched for type 2 diabetes: the Sea Islands Genetic African American Registry (Project SuGAR).Characterization of metabolic interrelationships and in silico phenotyping of lipoprotein particles using self-organizing mapsCardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver diseaseApolipoprotein B-containing lipoproteins in retinal aging and age-related macular degeneration.Triglycerides and cardiovascular risk.Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acidsMetabolic syndrome: from epidemiology to systems biology.The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women.MicroRNA-management of lipoprotein homeostasis.Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.Phosphorus supplement alters postprandial lipemia of healthy male subjects: a pilot cross-over trialMetabolic actions of insulin in men and womenNon-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD)Peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) stimulates VLDL assembly through activation of cell death-inducing DFFA-like effector B (CideB)Estrogen deficiency after menopause does not result in male very-low-density lipoprotein metabolism phenotype.Interleukin-6 mediates hepatic hypersecretion of apolipoprotein B.Extracellular nucleotides inhibit insulin receptor signaling, stimulate autophagy and control lipoprotein secretion.Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant.Low HDL-Cholesterol with Normal Triglyceride Levels is the Most Common Lipid Pattern in West Africans and African Americans with Metabolic Syndrome: Implications for Cardiovascular Disease Prevention.Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profileBaseline levels, and changes over time in body mass index and fasting insulin, and their relationship to change in metabolic trait clustering.Levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart diseaseA dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
P2860
Q21245690-A5FF5792-36CA-4493-B2FA-AFFE600CFF9FQ22241786-C830EAC8-EBBE-4211-90B6-6968C73A64B2Q24642118-18B7A894-083F-41D8-B192-03C6D1481B81Q26746279-98C2D5F5-CA05-4672-9CCD-EFB5CB436086Q26774776-8FAD7B60-C779-45EB-BBAC-6BBC65A9A071Q26777184-74A7A90C-CC0E-403D-9DD1-5D6A1E441A16Q27310235-67D5D758-047D-45EA-BECA-BCA386A569A6Q27968233-7885DF0F-220C-4E30-9E12-38C0AE7F327CQ28077776-2793CC3E-02F2-4EF9-A8F0-A5367496D45BQ28084990-011ED0D4-BC5D-441B-9505-6206D5C297C1Q28388174-ACEAECC9-3A52-4E3F-B7C1-D60BAE709FDCQ28538300-06065EF0-0585-420E-A3A0-AC65A4763D4EQ28541818-2A5F15D3-2529-46CD-94F2-240192192A91Q28749264-7FB92591-0925-4052-9978-F7F2015612A2Q28829926-0888A4F7-4387-457C-AB0F-2BAE7D02925BQ30433072-64C195A8-7C43-4BAF-951C-70094F1D7E81Q33577893-07DFE3FC-90F0-4280-B720-57FA82234654Q33602366-B5C9F687-ACE7-4FF5-B601-7CC890322CBBQ33607697-705C7F38-49DB-43A8-B835-0AEB87A71983Q33634096-FC87E1E1-DE32-484D-93E1-D52D1A126FD8Q33654016-A021DEAB-F24A-478B-AD54-D5B3AF703F3FQ33688639-C3E7DC88-740C-4AD5-A89C-C98BA32D9C45Q33691139-20641B14-5979-4A9D-A51E-2E59B759E29FQ33771752-C5836A7E-2C02-4B11-96CC-D8E9850F54E4Q33803431-CFCF6936-EC03-48D3-9B81-D5655D2C47CCQ33851062-8060EE5A-DDC4-44E3-BB63-8F51C4ED0201Q33887783-302DD68C-0635-45BA-A2AF-0B5DA5CE9ECAQ33943512-2CC35FD2-9FC0-4678-8B17-8D3ACB4A4AB9Q33945495-580F1B89-DD73-4ECD-B9AA-9780DB017F05Q34037347-F3B38F70-EC11-4328-91FE-6E5A06DFF714Q34074263-DBEEFA89-4C52-45F9-91C3-01EA224A89BCQ34086590-DD325338-76B4-4BB0-BF9F-CF226BE0784FQ34212081-EC3AC4BA-6024-4DA9-8FFA-DED9BEF2CE36Q34271095-774BDFA9-805D-49DC-BC96-324C7DB33DCAQ34314416-D1984EDF-53D0-4740-BEAB-0AC1DF176212Q34339896-8F1858CC-AFB6-45FA-8549-0A0B15CA4FF9Q34399408-D9B02701-9DEC-4046-BF89-DC75F5C3E844Q34404827-58FE740A-0A75-47A0-BAD1-656DE8059A93Q34443992-B4D20595-4334-4D2A-A87A-DF48D34D9BE9Q34473275-C73E1C33-7D3A-4669-8C10-B190A4DBB2CC
P2860
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Overproduction of very low-den ...... mia in the metabolic syndrome.
@en
Overproduction of very low-den ...... mia in the metabolic syndrome.
@nl
type
label
Overproduction of very low-den ...... mia in the metabolic syndrome.
@en
Overproduction of very low-den ...... mia in the metabolic syndrome.
@nl
prefLabel
Overproduction of very low-den ...... mia in the metabolic syndrome.
@en
Overproduction of very low-den ...... mia in the metabolic syndrome.
@nl
P921
P1476
Overproduction of very low-den ...... mia in the metabolic syndrome.
@en
P2093
Marja-Riitta Taskinen
Martin Adiels
P304
P356
10.1161/ATVBAHA.107.160192
P407
P577
2008-07-01T00:00:00Z